The NAD+ Decline: Inside the Cellular Energy Crisis of Aging and What the 2026 Trials Actually Show

There is a single molecule sitting at the center of almost everything your cells do to stay alive. It helps turn food into energy. It powers the enzymes that repair your DNA. It tells your mitochondria when to build more of themselves and when to clean house. It is called nicotinamide adenine dinucleotide, or NAD+, and one of the most consistent findings in modern aging research is that the amount of it inside your tissues falls as the years pass.

Presented By Our Partners

That decline has become one of the most closely watched stories in longevity science. If a cell’s NAD+ supply is a fuel tank, then aging looks, at the molecular level, a great deal like running the tank progressively lower. The question that has consumed laboratories from St. Louis to Oslo to Mayo Clinic is deceptively simple to state and fiendishly hard to answer: if you refill the tank, do you slow the machinery of aging itself, or do you simply make the gauge read full while the engine wears out anyway? In 2026, after a decade of mouse studies, contested measurements, and a growing wave of human trials, the field finally has enough data to give a more honest answer.

The Molecule Behind Every Heartbeat and Every Thought

NAD+ is what biochemists call a coenzyme, a helper molecule that dozens of enzymes cannot function without. It exists in two interconverting forms, the oxidized NAD+ and the reduced NADH, and the ratio between them serves as a kind of electrical currency that the cell uses to move energy around. Every time you break down glucose in glycolysis, every turn of the citric acid cycle inside your mitochondria, and every step of oxidative phosphorylation that ultimately produces ATP depends on NAD+ shuttling electrons back and forth. Without it, energy production stops within minutes.

But NAD+ is more than a metabolic workhorse. It is also consumed, meaning permanently used up, by a separate class of enzymes that act as the cell’s stress sensors and repair crews. The sirtuins, a family of seven proteins that includes SIRT1 and the mitochondrial SIRT3, are deacetylases that cannot operate without NAD+. They govern mitochondrial biogenesis, the fasting response, and the silencing of genes that should stay quiet. The PARP enzymes, chief among them PARP1, spring into action whenever DNA strands break, and they pull NAD+ apart to fuel the repair. A third group, the CD38 and CD157 enzymes, sit on cell surfaces and in immune cells and chew through NAD+ at remarkable speed.

This dual identity, both a recyclable energy carrier and a consumable signaling substrate, is exactly what makes NAD+ so vulnerable to the passage of time. Demand and supply drift out of balance, and the cell pays the price.

Why the Tank Runs Low: The Forces Draining NAD+ With Age

Researchers now describe the age-related fall in NAD+ as the product of three converging pressures rather than a single cause.

The first is rising consumption. The clearest culprit is CD38, the principal NADase in mammalian tissue. Work led by Eduardo Chini and colleagues at the Mayo Clinic established that CD38 expression climbs sharply with age and that this rise is a major driver of NAD+ depletion in multiple organs. Crucially, CD38 appears to be switched on by inflammation. As we age, senescent cells accumulate and pour out the cocktail of inflammatory signals known as the senescence-associated secretory phenotype. Immune cells responding to this low-grade, chronic inflammation, the phenomenon often called inflammaging, ramp up CD38 and accelerate the breakdown of the very molecule the tissue is trying to conserve. NAD+ decline and cellular senescence, in other words, feed each other.

The second pressure is rising repair debt. As DNA damage accumulates over a lifetime, PARP1 is activated more and more often, and each activation draws down the NAD+ pool. A cell under genomic stress is a cell spending its energy currency on emergency repairs rather than routine metabolism.

The third pressure is falling production. The body makes most of its NAD+ through the salvage pathway, which recycles nicotinamide back into the molecule. The rate-limiting enzyme in that pathway is NAMPT, and the work of Shin-ichiro Imai at Washington University in St. Louis has shown that NAMPT activity and the circulating form of the enzyme decline with age, reducing the cell’s capacity to keep up with demand. Less manufacturing capacity meeting higher consumption produces exactly the deficit that measurements keep finding.

The Mitochondrial Connection

Nowhere does the NAD+ shortfall matter more than in the mitochondria, the organelles that generate the bulk of a cell’s energy. Mitochondrial dysfunction is one of the recognized hallmarks of aging, and NAD+ sits upstream of much of it. The NAD+ to NADH ratio directly sets the pace of the electron transport chain. When NAD+ runs low, oxidative phosphorylation falters and cells produce less ATP while leaking more reactive oxygen species.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

The damage compounds because NAD+ also governs mitochondrial quality control. SIRT3, the mitochondrial sirtuin, depends on NAD+ to keep antioxidant defenses and metabolic enzymes properly tuned. Mitophagy, the housekeeping process that identifies and recycles broken mitochondria through the PINK1 and Parkin pathway, is similarly NAD+ sensitive. As the coenzyme dwindles, damaged mitochondria are cleared less efficiently and linger, dragging down the energy economy of the whole cell. This is why so many researchers view NAD+ not as one more item on the long list of aging mechanisms but as a hub that ties several of them together.

From Mouse to Human: What the Precursor Trials Show

The therapeutic logic that follows is intuitive. If NAD+ falls with age, supply the cell with the raw materials it needs to make more. Two precursors dominate the conversation. Nicotinamide riboside, or NR, was characterized as an NAD+ precursor through the work of biochemist Charles Brenner and reached the market as a supplement. Nicotinamide mononucleotide, or NMN, sits one step closer to NAD+ in the salvage pathway and has been championed in animal work by Imai and by Harvard’s David Sinclair.

In mice, the results have been genuinely striking. Precursor supplementation has improved insulin sensitivity, exercise capacity, neurological function, and vascular health across many studies. The harder question has always been whether any of this carries over to humans, and here the picture is more measured.

The most cited human result came in 2021, when a team at Washington University led by Samuel Klein and Shin-ichiro Imai reported in Science that NMN improved muscle insulin sensitivity in prediabetic, overweight and obese postmenopausal women. Subsequent trials reported that NMN improved aerobic capacity in amateur runners and, in a 2023 study, modestly improved six-minute walk performance and a subjective measure of general health. Nicotinamide riboside has been tested extensively as well, including a Phase II study suggesting improved functional mobility in peripheral artery disease.

The throughline across this body of work is consistent and worth stating plainly. The precursors reliably and safely raise the level of NAD+ and its metabolites in the blood. What remains far less certain is whether that biochemical bump translates into meaningful improvements in how people feel, function, or age, particularly in healthy adults rather than in patients with a specific metabolic deficit. The effect sizes have generally been small, the trials short, and the populations narrow.

The Brain Frontier

Some of the most interesting recent work has moved into neurology, where mitochondrial dysfunction is a core feature of disease. In the NADPARK trial, Norwegian researchers gave nicotinamide riboside to patients with early Parkinson’s disease and, using magnetic resonance spectroscopy, showed that the supplement actually raised NAD+ levels in the living human brain, an important proof that an oral precursor can reach the organ that matters most for cognitive aging. That finding has propelled a new generation of studies. Larger trials are now testing NR in early Parkinson’s with mitochondrial function and clinical progression as endpoints, and trials such as those examining NMN in mild cognitive impairment are following cognitive performance over months rather than weeks.

A 2026 review in Nature Aging singled out NAD+ augmentation as one of the more promising avenues for the prevention of both Alzheimer’s and Parkinson’s disease, precisely because the coenzyme supports the mitochondrial health of neurons, cells that are exquisitely dependent on a steady energy supply and poorly equipped to tolerate its loss. The operative word, however, is prevention rather than cure, and the operative tense is future. These are hypotheses being tested, not conclusions already reached.

The Measurement Problem

One reason the NAD+ story has been so contested is surprisingly mundane: the molecule is genuinely hard to measure. NAD+ is unstable and present in tissues at concentrations that demand careful sample handling and sensitive instruments. Modern estimates come from liquid chromatography coupled to mass spectrometry, performed in metabolomics laboratories where samples must be flash frozen and processed under tightly controlled conditions to prevent the molecule from degrading before it can be quantified. Brain NAD+ is now estimated noninvasively using phosphorus magnetic resonance spectroscopy, a technique that reads the molecule’s chemical signature through the skull.

These technical demands explain part of why the field has argued about something as basic as how much NAD+ actually declines with age. Reported drops have ranged widely depending on the tissue studied and the method used, and a measurement made carelessly can produce a number that is simply wrong. The maturing of metabolomics methods has been quietly as important to this field as any single drug candidate, because reliable answers about whether a therapy works depend entirely on reliable measurement of the thing it is supposed to change.

The Hype Gap

The science has also outrun itself in the marketplace. As an NPR investigation noted in 2026, NAD+ pills, and increasingly NAD+ intravenous infusions sold at wellness clinics, are marketed with longevity promises that the published evidence does not support. The gap between what has been demonstrated, that precursors can raise blood NAD+ and are generally well tolerated in the short term, and what is being sold, that they will extend your healthy lifespan, is wide.

Several legitimate cautions sit inside that gap. The long-term safety of years of high-dose supplementation in healthy people has not been established. NAD+ fuels cell proliferation, which has prompted reasonable questions, so far unresolved in humans, about whether flooding the system could feed existing cancers. Very high doses of nicotinamide can, paradoxically, inhibit the sirtuins that the whole strategy aims to support. And intravenous NAD+ in particular, despite its popularity and expense, rests on especially thin clinical evidence. None of this means the underlying biology is wrong. It means the responsible reading of the field is that NAD+ restoration is a serious and promising scientific hypothesis, not a proven anti-aging therapy.

The Next Generation: CD38 Inhibitors and NAMPT Activators

The most telling sign of where the science is heading is that some researchers have stopped focusing only on adding precursors and started targeting the machinery that controls NAD+ in the first place. If CD38 is draining the pool, then inhibiting CD38 should preserve it, and experimental compounds such as the inhibitor known as 78c have improved metabolic function in aged mice. If NAMPT is the production bottleneck, then activating it should raise output, and NAMPT activators including SBI-797812 and a compound called C8 have shown anti-aging effects in laboratory organisms. A further frontier combines NAD+ restoration with senolytics, the drugs that clear senescent cells, on the logic that removing the inflammatory cells that switch on CD38 might let an NAD+ boost finally stick. These approaches remain preclinical, but they reflect a more sophisticated view of the problem than simply pouring in more fuel.

What This Means For You

If you take away one idea, let it be this. The decline of NAD+ with age is real, well documented, and mechanistically important. It is one of the genuine connective threads running through mitochondrial dysfunction, DNA repair, inflammation, and cellular senescence. That makes it one of the most scientifically credible targets in all of longevity research.

What has not yet been proven is that swallowing a precursor supplement meaningfully slows aging or extends healthy life in people who are not already sick. The human trials that exist are mostly small, short, and focused on specific patient groups, and while they consistently show that you can raise NAD+ levels safely, the downstream benefits remain modest and uncertain. Anyone selling an NAD+ pill or an IV drip as a proven path to longevity is several large clinical trials ahead of the actual evidence.

For most people, the practical wisdom is unglamorous but well supported. The behaviors that reliably support healthy NAD+ metabolism are the same ones that support nearly every other system in the body. Regular exercise, particularly endurance and resistance training, activates NAMPT and raises NAD+ through the body’s own machinery. Avoiding chronic overnutrition reduces the metabolic stress that depletes the pool. Protecting sleep and managing chronic inflammation limits the CD38 activation that drains it. These cost nothing and carry no unknown long-term risks.

If you are curious about supplementation, the honest framing is that nicotinamide riboside and NMN appear safe in the short term and will almost certainly raise your NAD+ levels, but that you would be participating in an ongoing experiment rather than following settled medicine. That is a legitimate choice to make with open eyes, ideally in conversation with a physician who knows your history, especially if you have a personal or family history of cancer. Keep an eye on the trials now reading out, including those in cognitive aging and Parkinson’s disease, because the next two years of data will tell us far more than the past decade of mouse studies ever could. The energy crisis inside our aging cells is one of the most compelling problems in medicine. The work of solving it, properly and with proof, is only now reaching the point where the answers will be real.

This article is for educational purposes and does not constitute medical advice. Talk with a qualified healthcare professional before starting any supplement, particularly if you have an existing medical condition or take prescription medication.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.